Please assess the completion status of the following clinical trial:

Trial Title: Bronchodilator Responsiveness in Obliterative Bronchiolitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Obliterative bronchiolitis (OB) following allogeneic HSCT~* FEV1 to slow inspiratory vital capacity (VC) ratio (FEV1/VC)\<5th percentile~* FEV1 \<75% predicted or absolute FEV1 fall \>10% of pre-HSCT value~* evidence of OB by computed tomography scanning~* negative microbiological yields in bronchoalveolar lavage fluid~* chronic graft-versus-host disease score \>0~* negative history for bronchial asthma, chronic obstructive pulmonary disease or other significant respiratory disease.~Exclusion Criteria:~* inability to perform lung function maneuvers~* pre-existent chronic lung disease other than OB

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- albuterol-tiotropium (Type: EXPERIMENTAL): At visit 1, lung function measurements will be performed in triplicate before and 90 min after inhaling four separate doses of 100 μg of albuterol (Ventolin®) and soon after 18 μg of tiotropium bromide \[Spiriva®\] to ensure maximal or near-maximal bronchodilation. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber (Volumatic®) and tiotropium by a dry-powder device (Handihaler®).

Based on this trial design, predict the completion outcome and termination type (if applicable).